Core Insights - BioInvent International AB is presenting new data on its ongoing trial of BI-1206 in combination with rituximab and Calquence for non-Hodgkin's lymphoma at the 2025 ASH Annual Meeting [1] Company Summary - BioInvent is focused on the discovery and development of novel immune-modulatory antibodies for cancer immunotherapy [1] - The trial data indicates that the triple combination regimen is safe and well-tolerated [1] - Encouraging efficacy data has been reported as part of the trial findings [1] Industry Context - The presentation will take place at the American Society of Hematology Annual Meeting, highlighting the significance of the findings within the hematology field [1]